| Document |
Document Title |
|
WO/2010/112946A9 |
The invention relates to adamantane bisurea derivatives and their use. Adamantane bisurea derivatives are obtained by reaction of adamantane diamine with appropriate isocyanate, or by in situ preparation of adamantane isocyanate from ada...
|
|
WO/2010/127558A1 |
Substituted benzoyl urea compounds, preparation methods and pharmaceutical uses thereof are disclosed. The compounds are shown by general structure formula (I), wherein R1, R2 and R3 are defined as those in the description. The compounds...
|
|
WO/2010/128062A1 |
The invention relates to the use of O-imino-iso-urea compounds as source of radicals to polymerizable compositions comprising these O-imino-iso-urea and to new O-imino-iso-urea compounds. The O-lmino-isoureas compounds are compounds of t...
|
|
WO/2010/122968A1 |
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...
|
|
WO/2010/086878A3 |
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta. Further, the present invention relates to processes of prepari...
|
|
WO/2010/120138A2 |
The present invention relates to a salicylaldehyde chiral compound (chemical formula 1) and a naphtholaldehyde chiral compound (chemical formula 2), wherein a –OH group and a carbonyl group are adjacent to each other on a benzene ring....
|
|
WO/2010/080795A3 |
Provided is a complex of hydrogen peroxide and at least one compound represented by Formula (I): wherein X is ( ), -C(R3)3, -C=C(R3), -O(R3), -N(R3)2, or -S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, ...
|
|
WO/2010/112946A1 |
The invention relates to adamantane bisurea derivatives and their use. Adamantane bisurea derivatives are obtained by reaction of adamantane diamine with appropriate isocyanate, or by in situ preparation of adamantane isocyanate from ada...
|
|
WO/2010/113848A1 |
Disclosed is a compound represented by formula (I) or the like, which serves as an agent for treatment of diseases that are induced by production, secretion and/or deposition of amyloid β protein. Specifically disclosed is a compound re...
|
|
WO2010110555A2 |
The present invention relates to a method for obtaining optically pure amino acids, including optical resolution and optical conversion. The method of the present invention significantly shortens the time taken for optical transformation...
|
|
WO/2010/062490A3 |
The present invention provides methods of forming carbamates, ureas, and isocyanates. In certain embodiments these methods include the step of reacting an amine with an ester-substituted diaryl carbonate to form an activated carbamate wh...
|
|
WO/2010/062158A3 |
The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4") in the cocktail preparation of...
|
|
WO/2010/087318A1 |
Disclosed is a curable composition for a transfer material, which exhibits very good transferability in a nanoimprint process, while having a high selectivity between the dry etching rates by an argon gas and an oxygen gas. The curable c...
|
|
WO/2010/081683A1 |
The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
|
|
WO/2010/080795A2 |
Provided is a complex of hydrogen peroxide and at least one compound represented by Formula (I): wherein X is ( ), -C(R3)3, -C=C(R3), -O(R3), -N(R3)2, or -S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, ...
|
|
WO/2010/075636A1 |
The present invention provides in part a compound of Formula (I) or a pharmaceutically- acceptable salt or stereoisomer thereof: where R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea gr...
|
|
WO/2010/046181A3 |
The invention relates to substances for defoaming aqueous media. Said substances contain urea derivatives of formula (I) in the form of solid particles as defoaming agents. In formula (I), R1 is a hydrocarbon group comprising 4 to 30 car...
|
|
WO/2010/067005A1 |
The present invention relates to a method for preparing an allophanate, as well as to an allophanate and to a reduced viscosity polyisocyanate composition that contains the allophanate, intended for coating compositions, particularly pai...
|
|
WO/2010/065902A2 |
A compound of Formula (I), a pharmaceutically acceptable salt, or solvate thereof, complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal i...
|
|
WO/2010/063358A1 |
The invention relates to a method for producing a solution comprising urea urethanes and acting as a thixotropic agent, wherein at least two structurally different monohydroxy compounds are converted by an excess of toluylene diisocyanat...
|
|
WO/2010/062158A2 |
The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4") in the cocktail preparation of...
|
|
WO/2010/053128A1 |
Provided is a liquid crystal aligning agent capable of forming a liquid crystal alignment film the surface of which is rarely scratched or abraded when rubbed, and which exhibits excellent liquid crystal aligning properties and enables t...
|
|
WO/2010/046181A2 |
The invention relates to substances for defoaming aqueous media. Said substances contain urea derivatives of formula (I) in the form of solid particles as defoaming agents. In formula (I), R1 is a hydrocarbon group comprising 4 to 30 car...
|
|
WO/2010/035427A1 |
Disclosed is a urea compound represented by general formula (1). (In the formula, X1, X2 and X3 independently represent a hydrogen atom, an alkyl group or an aryl group. The aryl group may have one or more functional groups selected fro...
|
|
WO/2009/146539A8 |
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminome...
|
|
WO/2010/024298A1 |
Disclosed is a compound represented by formula (I) [wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the description] or a pharmaceutically acceptable salt or solvate thereof.
|
|
WO/2010/017470A1 |
The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composi...
|
|
WO/2010/017060A1 |
This invention relates to compounds of the Formula (I):or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC.
|
|
WO/2010/009508A1 |
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.
|
|
WO/2008/083054A3 |
Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also...
|
|
WO/2009/145989A3 |
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...
|
|
WO/2010/006085A1 |
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprisi...
|
|
WO/2009/130422A3 |
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...
|
|
WO/2009/146539A1 |
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminome...
|
|
WO/2009/145989A2 |
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...
|
|
WO/2009/069132A3 |
Compounds that are capable of inhibiting an activity of a reverse transcriptase are disclosed. Further disclosed are pharmaceutical compositions containing these compounds, and methods of inhibiting an activity of reverse transcriptase a...
|
|
WO/2009/132978A1 |
This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula (I) wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compo...
|
|
WO/2009/130422A2 |
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...
|
|
WO/2009/130317A1 |
The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the ...
|
|
WO/2008/145615A3 |
The present invention relates to the use of aminoazoline and urea derivatives for com- bating animal pests. The invention also relates to a method for controlling animal pests by using these compounds, to seed and to an agricultural and ...
|
|
WO/2009/121603A1 |
The invention relates to a method for producing at least one compound having at least one at least monosubstituted amino group. According to the invention, a starting substance supporting at least one amino group is reacted with an alcoh...
|
|
WO/2009/121607A1 |
The invention relates to a method for producing a compound having at least one at least monosubstituted amino group. According to the invention, a starting substance supporting at least one amino group is reacted with a reagent supportin...
|
|
WO/2009/124022A1 |
The invention provides amino- and amido-aminotetralin compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opio...
|
|
WO/2009/121843A1 |
Process for increasing the capacity of an existing urea plant comprising a high-pressure urea synthesis section and one or more recovery sections, wherein next to the existing urea plant a urea production unit, comprising a high-pressure...
|
|
WO/2009/089541A3 |
A method for designing a molecule capable of functioning as a PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a...
|
|
WO/2009/115491A1 |
The present invention relates to azolin-2-ylamino compounds of formulae (I) and (II), wherein n is 0 to 3; Ar is phenyl; A is a radical of formulae A1 or A2, wherein * indicates the point of attachment; X is S, O or N(R10); R7a-d are H, ...
|
|
WO/2009/053443A3 |
This invention provides new indane compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.
|
|
WO/2009/117095A1 |
The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are...
|
|
WO/2009/115040A1 |
Benzoylurea compounds having the structure of formula (I) and uses thereof, wherein: R1 and R2 are independently selected from H, F, Cl, Br and I; R3, R4, R5, R6 and R7 are independently selected from H, halogen, C1-C6alkyl, C1-C6alkoxyl...
|
|
WO/2009/106351A1 |
The present invention provides a compound of formula (I): wherein: R1 is a group selected from -CH2OH1-NHCOH and R2 is a hydrogen atom; or R1 together with R2 form the group -NHC(O)CH=CH-, wherein the nitrogen atom is bound to the carbon...
|
